EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) have been assigned an average recommendation of “Buy” from the five analysts that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have updated their coverage on […]
More Stories
NEXT’s (NXT) “Buy” Rating Reiterated at Shore Capital
Shore Capital restated their buy rating on shares of NEXT (LON:NXT – Free Report) in a research note published on...
Rathbones Group (LON:RAT) Earns “Buy” Rating from Shore Capital
Shore Capital reissued their buy rating on shares of Rathbones Group (LON:RAT – Free Report) in a research report report...
Warner Music Group (NASDAQ:WMG) Given New $28.00 Price Target at Barclays
Warner Music Group (NASDAQ:WMG – Get Free Report) had its price objective dropped by analysts at Barclays from $31.00 to...
JPMorgan Chase & Co. Cuts Zillow Group (NASDAQ:Z) Price Target to $79.00
Zillow Group (NASDAQ:Z – Free Report) had its price objective trimmed by JPMorgan Chase & Co. from $93.00 to $79.00...
Lords Group Trading (LON:LORD) Earns Buy Rating from Berenberg Bank
Berenberg Bank reissued their buy rating on shares of Lords Group Trading (LON:LORD – Free Report) in a research note...
Guggenheim Cuts Warner Music Group (NASDAQ:WMG) Price Target to $37.00
Warner Music Group (NASDAQ:WMG – Get Free Report) had its target price lowered by Guggenheim from $40.00 to $37.00 in...